Systematic Review of Genetic Polymorphisms Associated with Acute Pain and Relevant Acute Toxicities Induced by Radiotherapy for Head and Neck Cancer

Vivian Salama, Yimin Geng, Jillian Rigert, Clifton D. Fuller, Amy C. Moreno, Sanjay Shete, Cielito C. Reyes-Gibby
doi: https://doi.org/10.1101/2022.11.15.22282359

Abstract

Background/objective Pain is the most common acute toxicity following radiation therapy (RT) for head and neck cancer (HNC). The multifactorial origin of radiotherapy-induced pain makes it highly challenging to manage in HNC patients. Multiple studies have been conducted to identify different germline genetic variants associated with cancer pain, however few of them focused on RT-induced acute pain. In this systematic review, we summarize potential mechanisms of acute pain after radiotherapy in HNC focusing on oral cavity/oropharyngeal cancer and identify genetic variants associated with radiotherapy-induced acute pain and other relevant acute toxicities.

Methods A comprehensive search of Ovid Medline, EMBASE and Web of Science databases using concepts and terms including “Variants”, “Polymorphisms”, “Radiotherapy”, “Acute pain”, “Acute toxicity” published up to February 28, 2022 was performed by two reviewers. Review articles and citations were reviewed manually. The reported SNPs associated with RT-induced acute pain and toxicities were reported, and the molecular function of the associated genes and pathways were described based on genetic annotation using The Human Gene Database; GeneCards.

Results A total of 386 articles were identified electronically and an additional 8 articles were included after manual search. 39 articles were finally included. 51 variants were associated with 40 genes, of which 30 % had function in DNA damage response and repair, 25% in inflammatory and immune response, 17.5 % in cell death or cell cycle, and were associated with RT-inflammatory pain and acute mucositis or dermatitis. 4 variants in 4 genes were associated with neuropathy and neuropathic pain. 13 variants in 10 genes and were associated with RT-induced mixed types of post-RT-pain.

Conclusion Different types of pain develop after RT, including inflammatory pain (acute mucositis and acute skin reaction); neuropathic pain; nociceptive pain; and mixed oral pain. Genetic variants involved in DNA damage response and repair, cell death, inflammation and neuropathic pathways may affect pain presentation post-RT. These variants could be used for acute pain prediction and personalized pain management in HNC patients receiving RT.

Introduction

Head and neck squamous cell carcinoma (HNSCC) are composed of a heterogenous mix of malignant epithelial cancers that arises from the oral cavity, pharynx or larynx. Oral cavity and oropharyngeal (OC/OPC) squamous cell carcinoma, afflicted more than 54,000 patients in the U.S, in 2022 1.Management of OC/OPC is a stage-dependent multimodality approach that entails surgery, chemotherapy, and radiotherapy. Radiotherapy (RT) is a cornerstone for the management of OC/OPC patients. RT, especially after application of the novel RT techniques, has a favorable impact on the overall survival rates 2. Despite improvement in survival rates, various significant acute and sometimes chronic or permanent toxicities are reported during and after RT. RT-attributable toxicities, including mucositis, dermatitis and dysphagia, have significant negative impacts on patients’ quality of life (QOL) and may rarely even lead to death 3–5.

Oral/throat pain, the most common radiation-attributable acute toxicity during and after locoregional RT of OC/OPC, is associated with increase in analgesics use 6. About 68-86% of OC/OPC patients and about one-third of HNC patients present to the emergency department with uncontrolled pain 7–11. The control of RT-induced acute pain is challenging because of the complex nature and multiple mechanisms of pain in these patients. Baseline pain and associated RT toxicities such as mucositis, dermatitis, neuropathy, and dysphagia are considered the most common etiologies of RT-induced pain. In addition, pain due to surgery and/or chemotherapy are also observed in these patients 12–14. Most clinicians will prescribe opioids to OC/OPC patients during cancer therapy, with 15-40% of patients dependent on opioids for several months post therapy 15–17. The optimal use of opioids is a major clinical challenge. While trying not to undertreat patients with severe pain, potential overuse of opioids may negatively impact the health status and the quality of life of patients. Furthermore, for a subset of patients, the prolonged use of opioids increases the risk for drug abuse and addiction, which may negatively impact the QOL and increase the potential for overdose and death 18.

The mechanism of radiotherapy-induced cell death and normal tissue toxicities

Radiation therapy is a group of ionizing energy beams that induce DNA damage in cells, cancer cells being most susceptible due to their characteristic of rapid cell division. Direct DNA damage is induced by ionizing radiation to DNA, inducing DNA breaks (single-strand breaks (SSBs), double strand breaks (DSBs)) and covalent crosslinking of the complementary DNA strands 19, 20. Indirect DNA damage occurs through RT-induced generation of free radicals. For instance, reactive oxygen species (ROS) are produced by the interaction of ionizing radiation with the water molecules 21. After RT, the impairment of DNA repair mechanisms in cancer cells in addition to the accumulation of intracellular ROS induces cell injury and apoptosis, necrosis and cellular senescence 22–25. However, normal neighboring healthy tissues will also be exposed to ionizing radiation, inducing normal cell injury and maybe cell death despite the lower doses of radiation exposure. Normal tissue damage induces toxicities such as oral mucositis, dermatitis, and neuropathy leading to aggravation of RT-induced acute pain. The severity of RT-induced toxicities and pain is dependent on the total dose, fractions and the duration of radiation delivered to normal tissue in addition to the variation in tissue tolerance to radiation 26, 27.

Types and potential mechanisms of radiotherapy induced acute pain in OC/OPC patients

Adequate management of acute pain in OC/OPC patients during RT requires good understanding of the different types and mechanisms of RT-induced pain. Three main types of RT-induced acute pain have been identified in HNC patients receiving RT 28–30:

  1. Inflammatory pain

  2. Nociceptive pain

  3. Neuropathic pain

1. Inflammatory pain

Inflammatory pain, the most common type of RT-induced acute pain in HNC, is caused by activation of inflammatory and immune cells in response to tissue injury and infections induced by RT 21, 31. Inflammatory and immune cells in addition to RT-induced damaged cells release inflammatory mediators such as pro-inflammatory cytokines: interleukin (IL)-1β, IL-6, NF-kB, prostaglandins (PG), and tumor necrosis factor-α (TNF-α) 21, 32, 33. These cytokines induce more recruitment of immune and inflammatory cells, inducing more damage of tissues 34. Oral/pharyngeal mucositis and neck dermatitis are the most common inflammatory reactions induced by RT 21, 33, 35, 36. Different signaling pathways involved in RT-induced mucositis and dermatitis have been identified, and they may contribute to RT-induced inflammatory pain, such as: nuclear factor-κB (NF-κB) signaling which upregulates other pathways such as COX2 pathway and downstream tyrosine kinase receptor pathways (e.g. PI3K/AKT signaling and MAPK signaling). Other signaling pathways such as DNA damage checkpoints, cell cycle pathways, WNT/B-catenin and integrin signaling, VEGF signaling, glutamate receptor signaling and IL-6 signaling, have also been identified in correlation with RT-induced mucositis 36, 37.

2. Nociceptive pain

Nociceptive pain is caused by direct damage to non-neural tissue, often caused by an external injury which stimulates nociceptive receptors 30. Noxious stimuli are released from either damaged cancer, normal cells or from inflammatory/immune cells recruited after RT 38. Noxious stimuli activate the peripheral sensory neurons through stimulation of afferent sensory neurons which transmit the action potential to neuronal bodies where calcium influx occurs, leading to the release of neurotransmitters (e.g.: substance-P, glutamate, γ-aminobutyric acid (GABA), adenosine triphosphate (ATP), glycine, dopamine, norepinephrine, nitric oxide, and serotonin) which bind to the post-synaptic membrane receptors. The signal then reaches the second order neuron and is transmitted to the somatosensory cortex of the brain where the pain is perceived 39–43. The trigeminal nerves and the facial nerves (CN VII) play important roles in pain perception in the head and neck 44. RT-damaged cells and infiltrating immune cells release multiple noxious stimuli. Cytokines and inflammatory mediators released from infiltrating immune cells such as IL-1, TNF-α and IL-6 induce nociceptor sensitization. In addition, the acidic pH of the tumor microenvironment and extracellular ATP act as noxious stimuli to nociceptors at the cancer site 45.

3. Neuropathic pain

Neuropathic pain is caused by damage to nerves or nervous system 46. RT directly injures the somatosensory nervous system promoting pain signal transmission and peripheral neuropathic pain. RT induces DNA damage which induces apoptosis. Apoptosis is induced through p53 activation which activates the cascade to execute cell death 47, 48. Endothelial cell death reduces blood flow to peripheral nerves, including damage and eventual neuronal fibrosis. Furthermore, ionizing radiation and ROS released after RT, cause neuronal cell stress and direct nerve damage. In RT of HNC, the brachial plexus are the neural tissues at high risk of damage. Overexpression of p53 induces apoptosis of neurons after radiation exposure 49. Furthermore, RT induces inflammation and infiltration by immune cells, resulting in immune-mediated peripheral neuropathy. Chronic inflammation in the nervous system microenvironment promotes neuron loss with fibrosis, resulting in chronic neuropathic pain 50.

Genetic variants associated with radiotherapy induced acute pain

Advances in molecular and genetic technologies have motivated researchers and scientists toward exploring the human genome and analyzing genetic variations and their correlations with different diseases and treatment outcome.

RT-induced acute pain presents a significant morbidity burden on OC/OPC patients receiving RT and drastically reduces patients’ quality of life. In an effort to better predict and optimize pain management approaches, various cellular and molecular approaches have been widely explored recently to identify the genomic biomarkers for patients vulnerable to develop RT-induced pain, and the influence of these genetic variants on pain modulation and analgesic response 51, 52. The advanced technologies in human genome sequencing allowed deep understanding of the genetic variations and mutations related to cancer treatment associated pain. Single nucleotide polymorphisms (SNPs) are the most common DNA sequence variations. These genetic polymorphisms are stable markers and easily and reliably assayed to explore the extent to which genetic variation might prove useful in identifying patients with cancer at high-risk of pain development and their response to pain therapies 53. Likewise, these candidate SNPs could be used in building robust predictive models for pre-treatment prediction of acute as well as chronic toxicities for personalized management and precision medicine 54.

Given the multifactorial and complex etiology of RT-induced pain in HNC patients, the challenges in managing RT-associated pain, and the adverse impact of pain on patients’ quality of life, the aim of this literature review is to identify predictive genetic variants and pathways associated with RT-induced pain and related phenotypes. This synthesis of the current literature will use provide the basis to develop predictive models of RT-induced acute pain to assist with personalized analgesic therapy.

Materials and Methods

Search Strategies

We conducted a systematic search of databases including Ovid MEDLINE, Ovid Embase, and Clarivate Analytics Web of Science, for publications in English language from the inception of databases to February 28, 2022. The following concepts were searched using subject headings and free text keywords as needed, “radiotherapy”, “radiation therapy”, “pain”, “neuropathy”, “analgesics”, “opioid”, “acute toxicity”, “mucositis”, “dermatitis”, “single nucleotide polymorphism”, “genetic variation”, “genetic variability”, and “genetic predisposition” etc. The terms were combined using AND/OR Boolean Operators. Animal studies, in vitro studies, and conference abstracts were removed from the search result. Handsearching of journals and publisher databases and manually checking the reference lists of journal articles were also conducted to supplement the electronic database search. The complete electronic database search strategies were detailed in Supplementary Tables S1–S3.

Inclusion criteria

The included studies met all of the following inclusion criteria: 1) articles published in English, 2) human studies in any type of cancers, 3) genetic polymorphisms reported to be significantly associated with RT-induced pain in different phenotypes (Inflammatory [Mucositis, dermatitis], neuropathy, nociceptive pain or mixed oral/throat pain). We included variants associated with our phenotypes in any type of cancer, for comprehensive search intent and to identify new SNPs identified in other cancers that need more focus in HNC.

Exclusion criteria

Articles were excluded if they met any of the following criteria: 1) non-genetic article or no genetic association study, 2) not radiotherapy induced pain or toxicity, 3) meta-analysis, or review article, 4) articles written in languages other than English, 5) clinical trials, 6) non-human study, or not blood or buccal DNA or 7) Other unrelated phenotypes like dysphagia, gastrointestinal toxicities (e.g. diarrhea).

Functional annotation

Manual functional annotation of the identified genes was done using GeneCards database. The function of each gene was assigned according to the most common functional pathway annotated in the GenCards and the relevant studies published online. 55, 56 We divided the collected variants and genes into three groups: 1) variants associated with RT-induced inflammatory pain including; RT-induced acute toxicities; acute mucositis and acute dermatitis (or acute skin reaction), 2) variants associated with other types of RT-induced acute pain (including post RT-pain, post-RT throat/mouth/neck pain and neuropathic pain/neuropathy)

Figure

Flow Chart of systematic review of SNPs associated Radiation-induced acute pain and relevant acute toxicities.

Results

1 Variants associated with radiotherapy induced inflammatory pain

Mucositis and acute skin reactions are the most common acute reactions reported following RT. 51 variants in 40 genes were associated with radiotherapy induced inflammatory pain and acute reactions including mucositis or dermatitis. (Table 1). Table 2 shows the biological functions and pathways of the genes associated with RT-induced acute mucositis and acute skin reaction. We found that 12 genes (32%) were involved in DNA damage and DNA repair pathways. 10 genes (19.5%) were involved in inflammatory pathways and immune systems, 7 genes (19.5%) were regulating cell death, apoptosis, autophagy or cell cycle pathways, 6 genes (17%) were involved in metabolisms and microenvironment functional pathways, 5 genes were functionally involved in other functional pathways. (Figure 2, table 2)

View this table:
Table 1:

Summary of literature search of variants associated with radiotherapy induced acute inflammatory pain.

View this table:
Table 2:

Pathways and biological functions of genes associated with radiotherapy induced acute inflammatory pain.

Figure 1:
Figure 1: Types and potential mechanisms of radiotherapy induced acute pain.

1- Radiotherapy in head and neck cancer induces DNA damage of cancer cells and normal neighbor cells and release of reactive oxygen species (ROS). DNA damage induces activation of DNA repair mechanisms which is impaired in cancer cells. Impairment of repair of damaged DNA induces activation of cell death through stimulation of apoptosis processes. Normal tissue death induces mucositis and dermatitis causing inflammatory pain. 2- Radiotherapy induces activation of immune responses and inflammatory cells which release inflammatory mediators such as cytokines and chemokines inducing inflammatory pain. Furthermore, these inflammatory mediators act as noxious stimuli, stimulating nociceptors to induce nociceptive pain. 3- Radiotherapy induces direct mechanical and thermal damage in addition of change in the microenvironment creating an acidic pH and increase in the adenosine triphosphate (ATP), and release of bradykinin and substance P which act as nociceptors stimuli inducing nociceptive pain. Radiotherapy induces direct nerve injury and inflammation of peripheral nervous system, and fibrosis in the connective tissue can also induce neuropathic pain.

Figure 2:
Figure 2: Pie chart of genes associated with radiotherapy induced inflammatory pain;

showing the frequency of genes involved different pathways.

2 Variants associated with radiotherapy induced Neuropathic pain

Neuropathic pain is one of the common types of pain developed after receiving RT in HNC. Few studies focused on identification of SNPs associated with radiotherapy-induced neuropathic pain. Reyes-Gibby et.al study was the only literature published to identify SNPs associated with neuropathy and neuropathic pain in HNC. 4 variants in 4 genes were identified, associated with radiotherapy induced neuropathic pain. (Table 3)

View this table:
Table 3:

Summary of literature search of variants associated with radiotherapy induced acute neuropathic pain

3 Variants associated with mixed types of radiotherapy induced acute pain

Our literature search revealed some studies identified SNPs associated with post RT-pain without classification of type of pain, we considered this phenotype as mixed types of pain. 13 variants in 10 genes associated with RT-induced Throat/Neck pain and other mixed types of post RT-pain as main phenotype (Table 4).3 genes (21.4%) are involved in cell death and apoptosis pathways, 3 genes (21.4%) are involved in metabolic and microenvironment processes; EGFL6 gene plays a role in angiogenesis 93, aquaporin gene AQP7 which plays a rule in water transport through water-selective membrane channel 94, and PLAUR gene which plays a role in proteolysis-independent signal transduction 95. 1 gene are enriched in neurotransmission/neuropathy pathways or play roles as nociceptors stimuli,1 gene (1%) has a function in DNA damage responses pathway; ATM gene 96. (Figure 3, Table 5).

View this table:
Table 4:

Summery of literature search of variants associated with other types of radiotherapy induced acute pain.

View this table:
Table 5:

Pathways and biological functions of genes associated with mixed types of radiotherapy induced acute pain.

Figure 3:
Figure 3: Pie chart of genes associated with radiotherapy-induced mixed types of pain;

showing the frequency of genes involved different pathways.

Discussion

Acute pain is a significant toxicity during and after radiotherapy in HNC, resulting in increase in disability risks, increase in morbidity and decrease in the quality of life of these patients. Acute pain control resulting from RT is highly challenging due to the multifactorial clinical, genetic and molecular mechanisms. Understanding the potential mechanisms and the host genetic variability can help in pain prediction, prevention and in decision making for personalized pain management. To date, few studies explore the mechanisms of acute pain in HNC patients receiving RT. Moreover, very few variants have been identified associated with RT-induced acute pain and relevant acute toxicities in HNC. In this systematic review, we studied the different potential mechanisms for acute pain developed during RT in HNC cancer patients.SNPs identified associated with RT-induced acute pain, mucositis and dermatitis in different types of cancers were collected for comprehensive search.

Our review found that DNA damage, DNA repair, cell death and inflammation are essential in inducing inflammatory pain following RT. Variants detected in genes involved in DNA damage response or DNA repair are associated with acute toxicities (mucositis and dermatitis) related to RT. 18 published studies evaluated the association of variants in DNA damage and DNA repair with RT-induced acute toxicities, 6 out of the 18 studies focused on variants in X-Ray Repair Cross Complementing 1 gene (XRCC1) as a DNA repair gene highly associated with radiotherapy toxicity 61, 63, 74, 75, 98. Other variants in DNA damage and repair genes; XRCC2, XPD, ERCC1, ZNF24, NBN, Ku70, ATM, CHEK1, RAD51C, ERCC2, PMS1, MLH1 were associated with RT-acute toxicities, these results matched our study of the potential mechanisms of inflammatory pain induced by RT 22. Additionally, 11 studies identified variants in genes involved in inflammatory pathways and immune systems including; TNF-α 60, 96, 99, STING1 100, HLA-DQB158, TNFRSF1A 64, GHRL 65, PLA2G2F/ IIF 101, IFNG 80, IL12RB2 91 and NF-κβ 96, these variants were associated with RT-induced inflammatory pain and mixed throat pain. Studies showed that activation of inflammatory and immune cells after RT induces release of inflammatory cytokines and chemokines promoting more cell damage inducing inflammatory pain in addition to activation of nociceptors causing nociceptive pain 32, 33, 102–104. Reyes-Gibby et.al, studied the rule of cytokines in pain activation and sensitization 53, 105. Variants in genes regulating release of pro-inflammatory mediators as cytokines and chemokines are shown here in our review.

Few studies focused on neuropathic pain induced by RT, Reyes-Gibby et.al identified 4 SNPs in 4 genes (SNX8, PCP2, RORA and KNG1) correlated with neuropathy in HNC 92. Although substance-P and other neurotransmitters as excitatory amino acids exaggerates pain response 53, 106, no study have identified any variant in Substance-P or other neurotransmitters amino acids correlated with RT-induced pain, more studies are needed to identify the SNPs related to RT-induced neuropathy and neuropathic pain, specially variants in genes involved in neuronal plasticity and neuroinflammatory pathways. Other cell signaling pathways including cell cycle and NF-kB pathway (CCND1) 67, 68, autophagy (ATG16L2, ATG10) 62, wnt/β-catenin (APC, GSK3β) 71 and angiogenesis (EDN1)69 regulating genes were associated with RT related acute mucositis and dermatitis.

Studies included in this review, used either candidate gene approach or genome wide association analysis approach (GWAS), and interestingly through GWAS studies collected, we declared variants in genes involved in different/new pathways other than the common potential mechanisms of RT-induced pain, associated with RT-induced acute pain and toxicities. Sckack et.al conducted GWAS in HNC patients and identified candidate (rs1131769) in DNAJC18 gene regulating a chaperon molecules protecting cellular proteins, significantly associated with oral mucositis (OM) after RT 57. Yang et.al did GWAS of NPC patients and identified variant (rs117157809) in Tankyrase (TNKS) gene regulating telomere capping and maintenance of telomerase activity, is significantly associated with RT-induced OM 59. Li et.al, identified GWAS risk loci (rs1265081) in CCHCR1 gene regulating cellular process as keratinocyte proliferation, differentiation and EGFR pathways, associated with RT-induced OM in HNC patients 58, while Rattay et.al, identified variant (rs12554549) in PTPN gene regulating cell growth, differentiation and oncogenic transformation, associated with RT-induced acute skin ulceration in breast cancer patients 78. Genetic variants involved in oxidative stress response and ROS metabolism pathways (e.g. GSTM1 and NOS3) were associated with RT acute skin toxicity in breast cancer patients 81, 107

Although we did a comprehensive review to identify different potential mechanisms, including molecular pathways and genetic variants associated with RT-induced acute pain and relevant acute toxicities, there are limitations in our review. such as we focused on the most common acute toxicities being the common risk of acute pain as oral mucositis and dermatitis, while there are other acute toxicities could be relevant such as dysphagia. We did a comprehensive search covering all types of cancers, since studies focused on HNC were few and we would like to highlight other variants detected in other cancer types to be validated and focused on in future studies. Furthermore, many studies didn’t specify the type of pain detected either inflammatory, nociceptive or neuropathic, while they only mentioned post-RT pain or throat pain, we involved these variants under the group of other types/mixed pain. These studies collected, are just association studies, however, mechanistic studies must be done to test the mechanistic effect of these variants on the phenotype development and alteration of the different pathways associated. These identified candidates need further validation through more studies replication. More comprehensive analysis of the other candidates relevant to different types pf pain not associated with cancer or RT, is considered in our future plans.

Our future directions include validating these genetic variants and developing a predictive algorithm for pain prediction and management optimization using genetic candidates identified in out HNC cohort.

Conclusion

Multiple studies were conducted to identify different variants associated with cancer pain and cancer treatment induced pain. However, few of them focused on radiotherapy induced acute pain which is considered almost the most common acute toxicity following RT. We did a comprehensive literature review to identify the variants and genes that have been previously reported to have association with radiotherapy induced acute pain phenotypes including; mucositis, dermatitis (Inflammatory pain), neuropathic, nociceptive pain and mixed oral/mouth pain. Our review revealed that pain is a complex symptom following RT in OC/OPC patients due to its multifactorial origin and different phenotypes of its representation. DNA damage/ repair, inflammatory pathways, apoptosis, cell death, and neuropathy pathways are the most common pathways behind the development of radiotherapy-related acute toxicities and acute pain. Furthermore, there is a need for a comprehensive understanding of the genetic profile in addition to the clinical and treatment background of those patients who have high risk to develop acute pain following RT and to identify a more standardized algorithm for personalized management of acute RT-induced pain to maintain pain relief during RT and improve patients’ outcome and quality of life.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Abbreviations

HNSCC
Head and neck squamous cell carcinoma
OC/OPC
Oral cavity and oropharyngeal cancer
HPV
Human papilloma virus
RT
Radiotherapy
QOL
Quality of life
SSB
Single strand breaks
DSB
Double strand breaks
ROS
Reactive oxygen species
HNC
Head and neck cancer
NPC
Nasopharyngeal cancer
IL
Interleukins
PG
Prostaglandins
TNF
Tumor necrosis factors
Gy
Gray
VEGF
vascular endothelial growth factor signaling
GABA
γ-aminobutyric acid
NSCLC
Non-Small Cell Lung Cancer
NGF
Nerve growth factor
ATP
Adenosine triphosphate
SNPs
Single nucleotide polymorphisms
DDR
DNA damage response

References

  1. 1.↵
    Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Kong M, Hong SE, Choi J, Kim Y. Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer. Radiat Oncol J. 2013;31(1):1–11.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Muzumder S, Srikantia N, Udayashankar AH, Kainthaje PB, John Sebastian MG. Burden of acute toxicities in head-and-neck radiation therapy: A single-institutional experience. South Asian J Cancer. 2019;8(2):120–3.
    OpenUrl
  6. 6.↵
    Rosenthal DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson Symptom Inventory, head and neck module. Head Neck-J Sci Spec. 2007;29(10):923–31.
    OpenUrl
  7. 7.↵
    Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.
    Malik A, Sukumar V, Pai A, Mishra A, Nair S, Chaukar D, et al. Emergency Department Visits by Head-and-Neck Cancer Patients. Indian J Palliat Care. 2019;25(4):535–8.
    OpenUrl
  9. 9.
    Delgado-Guay MO, Kim YJ, Shin SH, Chisholm G, Williams J, Allo J, et al. Avoidable and unavoidable visits to the emergency department among patients with advanced cancer receiving outpatient palliative care. J Pain Symptom Manage. 2015;49(3):497–504.
    OpenUrlCrossRefPubMed
  10. 10.
    Caterino JM, Adler D, Durham DD, Yeung SJ, Hudson MF, Bastani A, et al. Analysis of Diagnoses, Symptoms, Medications, and Admissions Among Patients With Cancer Presenting to Emergency Departments. JAMA Netw Open. 2019;2(3):e190979.
    OpenUrl
  11. 11.↵
    Reyes-Gibby CC, Melkonian SC, Hanna EY, Yeung SJ, Lu C, Chambers MS, et al. Cohort study of oncologic emergencies in patients with head and neck cancer. Head Neck. 2017;39(6):1195–204.
    OpenUrl
  12. 12.↵
    Shuman AG, Terrell JE, Light E, Wolf GT, Bradford CR, Chepeha D, et al. Predictors of pain among patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138(12):1147–54.
    OpenUrlCrossRefPubMed
  13. 13.
    Rosenthal DI, Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol. 2009;19(1):29–34.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Ren JL, Rojo RD, Perez JVD, Yeung SJ, Hanna EY, Reyes-Gibby CC. Variations in pain prevalence, severity, and analgesic use by duration of survivorship: a cross-sectional study of 505 post-treatment head and neck cancer survivors. BMC Cancer. 2021;21(1):1304.
    OpenUrl
  15. 15.↵
    Smith WH. Prolonged Opioid Dependence Following Post-Operative Head and Neck Radiation Therapy. ASTRO. 2018;102(3).
  16. 16.
    McDermott JD, Eguchi M, Stokes WA, Amini A, Hararah M, Ding D, et al. Short- and Long-term Opioid Use in Patients with Oral and Oropharynx Cancer. Otolaryngol Head Neck Surg. 2019;160(3):409–19.
    OpenUrl
  17. 17.↵
    Muzumder S, Nirmala S, Avinash HU, Sebastian MJ, Kainthaje PB. Analgesic and Opioid Use in Pain Associated with Head-and-Neck Radiation Therapy. Indian J Palliat Care. 2018;24(2):176–8.
    OpenUrl
  18. 18.↵
    Jairam V, Yang DX, Verma V, Yu JB, Park HS. National Patterns in Prescription Opioid Use and Misuse Among Cancer Survivors in the United States. JAMA Netw Open. 2020;3(8):e2013605.
    OpenUrl
  19. 19.↵
    Thopan P, Yu L, Brown IG, Tippawan U. Low-Energy Ion-Species-Dependent Induction of DNA Double-Strand Breaks: Ion Energy and Fluence Thresholds. Radiat Res. 2017;188(4):426–32.
    OpenUrl
  20. 20.↵
    Van Der Schans GP. Gamma-ray induced double-strand breaks in DNA resulting from randomly-inflicted single-strand breaks: temporal local denaturation, a new radiation phenomenon? Int J Radiat Biol Relat Stud Phys Chem Med. 1978;33(2):105–20.
    OpenUrlPubMed
  21. 21.↵
    Kim K, McBride WH. Modifying radiation damage. Curr Drug Targets. 2010;11(11):1352–65.
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    Saha S, Woodbine L, Haines J, Coster M, Ricket N, Barazzuol L, et al. Increased apoptosis and DNA double-strand breaks in the embryonic mouse brain in response to very low-dose X-rays but not 50 Hz magnetic fields. J R Soc Interface. 2014;11(100):20140783.
    OpenUrlCrossRefPubMed
  23. 23.
    Verheij M, Bartelink H. Radiation-induced apoptosis. Cell Tissue Res. 2000;301(1):133–42.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.
    Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009;11(8):973–9.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res. 2004;162(1):1–19.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. Oncologist. 2002;7(2):136–43.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    Karri J, Lachman L, Hanania A, Marathe A, Singh M, Zacharias N, et al. Radiotherapy-Specific Chronic Pain Syndromes in the Cancer Population: An Evidence-Based Narrative Review. Adv Ther. 2021;38(3):1425–46.
    OpenUrl
  28. 28.↵
    Lai Y-H. Mechanisms and Models of Pain in Head and Neck Cancer Irradiation. PHD Dissertation, Raleigh, North Carolina, 2020.2020.
  29. 29.
    Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120(11):3742–4.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Kosek E, Cohen M, Baron R, Gebhart GF, Mico JA, Rice ASC, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157(7):1382–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25(11):2739–49.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    Neta R, Oppenheim JJ. Radioprotection with cytokines--learning from nature to cope with radiation damage. Cancer Cells. 1991;3(10):391–6.
    OpenUrlPubMedWeb of Science
  33. 33.↵
    Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, et al. IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A. 2004;101(8):2452–7.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    Schaue D, Kachikwu EL, McBride WH. Cytokines in radiobiological responses: a review. Radiat Res. 2012;178(6):505–23.
    OpenUrlCrossRefPubMed
  35. 35.↵
    Muanza TM, Cotrim AP, McAuliffe M, Sowers AL, Baum BJ, Cook JA, et al. Evaluation of radiation-induced oral mucositis by optical coherence tomography. Clin Cancer Res. 2005;11(14):5121–7.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    Maria OM, Eliopoulos N, Muanza T. Radiation-Induced Oral Mucositis. Front Oncol. 2017;7:89.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Sonis ST. Pathobiology of mucositis. Semin Oncol Nurs. 2004;20(1):11–5.
    OpenUrlCrossRefPubMed
  38. 38.↵
    Epstein JB, Wilkie DJ, Fischer DJ, Kim YO, Villines D. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009;1:26.
    OpenUrlCrossRefPubMed
  39. 39.↵
    Kendroud S, Fitzgerald LA, Murray I, Hanna A. Physiology, Nociceptive Pathways. StatPearls. Treasure Island (FL) 2022.
  40. 40.
    Dafny N. Pain Principles. Neuroscience online. 2020.
  41. 41.
    Abbadie C, Brown JL, Mantyh PW, Basbaum AI. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience. 1996;70(1):201–9.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.
    Abbadie C, Trafton J, Liu H, Mantyh PW, Basbaum AI. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci. 1997;17(20):8049–60.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    Henry JL, Sessle BJ, Lucier GE, Hu JW. Effects of substance P on nociceptive and non-nociceptive trigeminal brain stem neurons. Pain. 1980;8(1):33–45.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    Frunza A, Slavescu D, Lascar I. Perineural invasion in head and neck cancers - a review. J Med Life. 2014;7(2):121–3.
    OpenUrl
  45. 45.↵
    Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8(9):705–13.
    OpenUrlCrossRefPubMedWeb of Science
  46. 46.↵
    IASP. IASP Task Force on Taxonomy. Classification of Chronic Pain. Second. Seattle: IASP Press; 1994. [Google Scholar].
  47. 47.↵
    Jin S. Role of p53 in Anticancer Drug Treatment- and Radiation-Induced Injury in Normal Small Intestine. Cancer Biol Med. 2012;9(1):1–8.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    Reyes-Gibby CC, Melkonian SC, Wang J, Yu RK, Shelburne SA, Lu C, et al. Identifying novel genes and biological processes relevant to the development of cancer therapy-induced mucositis: An informative gene network analysis. PLoS One. 2017;12(7):e0180396.
    OpenUrl
  49. 49.↵
    Gao Y, Sun N, Wang L, Wu Y, Ma L, Hong J, et al. Bioinformatics Analysis Identifies p53 as a Candidate Prognostic Biomarker for Neuropathic Pain. Front Genet. 2018;9:320.
    OpenUrl
  50. 50.↵
    Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and musculoskeletal complications in cancer survivors. PM R. 2011;3(11):1041–54.
    OpenUrlCrossRefPubMed
  51. 51.↵
    Zorina-Lichtenwalter K, Meloto CB, Khoury S, Diatchenko L. Genetic predictors of human chronic pain conditions. Neuroscience. 2016;338:36–62.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Mogil JS. Pain genetics: past, present and future. Trends Genet. 2012;28(6):258–66.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    Reyes-Gibby CC, Wu X, Spitz M, Kurzrock R, Fisch M, Bruera E, et al. Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol. 2008;9(8):777–85.
    OpenUrlCrossRefPubMedWeb of Science
  54. 54.↵
    Lee S, Kerns S, Ostrer H, Rosenstein B, Deasy JO, Oh JH. Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018;101(1):128–35.
    OpenUrl
  55. 55.↵
  56. 56.↵
    Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016;54:1 30 1–1 3.
    OpenUrlCrossRefPubMed
  57. 57.↵
    Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM, et al. A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. British Journal of Cancer. 2022.
  58. 58.↵
    Li Q, Liang Y, Liu Z, Yu C. Associations of GWAS-Identified Risk Loci with Progression, Efficacy and Toxicity of Radiotherapy of Head and Neck Squamous Cell Carcinoma Treated with Radiotherapy. Pharmgenomics Pers Med. 2021;14:1205–10.
    OpenUrl
  59. 59.↵
    Yang DW, Wang TM, Zhang JB, Li XZ, He YQ, Xiao RW, et al. Genome-wide association study identifies genetic susceptibility loci and pathways of radiation-induced acute oral mucositis. J Transl Med. 2020;18(1).
  60. 60.↵
    Mlak R, Powrozek T, Brzozowska A, Homa-Mlak I, Mazurek M, Golebiowski P, et al. The relationship between TNF-alpha gene promoter polymorphism (−1211 T > C), the plasma concentration of TNF-alpha, and risk of oral mucositis and shortening of overall survival in patients subjected to intensity-modulated radiation therapy due to head and neck cancer. Support Care Cancer. 2020;28(2):531–40.
    OpenUrlPubMed
  61. 61.↵
    Yang Z, Liu Z. Potential Functional Variants in DNA Repair Genes Are Associated with Efficacy and Toxicity of Radiotherapy in Patients with Non-Small-Cell Lung Cancer. J Oncol. 2020;2020:3132786.
    OpenUrl
  62. 62.↵
    Yang Z, Liu Z. Potentially functional variants of autophagy-related genes are associated with the efficacy and toxicity of radiotherapy in patients with nasopharyngeal carcinoma. Mol Genet Genomic Med. 2019;7(12):e1030.
    OpenUrl
  63. 63.↵
    Ankita Gupta DM, Sushmita Ghoshal & Arnab Pal. XRCC1 (rs25487) polymorphism is associated with severe oral mucositis and poor treatment response after radiotherapy for oropharyngeal carcinoma. Oral Cancer volume 3, pages 37–47 (2019). 2019.
    OpenUrl
  64. 64.↵
    Brzozowska A, Powrozek T, Homa-Mlak I, Mlak R, Ciesielka M, Golebiowski P, et al. Polymorphism of Promoter Region of TNFRSF1A Gene (−610 T > G) as a Novel Predictive Factor for Radiotherapy Induced Oral Mucositis in HNC Patients. Pathol Oncol Res. 2018;24(1):135–43.
    OpenUrl
  65. 65.↵
    Brzozowska A, Homa-Mlak I, Mlak R, Golebiowski P, Mazurek M, Ciesielka M, et al. Polymorphism of regulatory region of GHRL gene (−2531C>T) as a promising predictive factor for radiotherapy-induced oral mucositis in patients with head neck cancer. Head Neck. 2018;40(8):1799–811.
    OpenUrl
  66. 66.
    Brzozowska A, Mlak R, Homa-Mlak I, Golebiowski P, Mazurek M, Ciesielka M, et al. Polymorphism of regulatory region of APEH gene (c.-521G>C, rs4855883) as a relevant predictive factor for radiotherapy induced oral mucositis and overall survival in head neck cancer patients. Oncotarget. 2018;9(51):29644–53.
    OpenUrl
  67. 67.↵
    Guo C, Huang Y, Yu J, Liu L, Gong X, Huang M, et al. The impacts of single nucleotide polymorphisms in genes of cell cycle and NF-kB pathways on the efficacy and acute toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2017;8(15):25334–44.
    OpenUrl
  68. 68.↵
    Wang J, Guo C, Gong X, Ao F, Huang Y, Huang L, et al. The impacts of genetic polymorphisms in genes of base excision repair pathway on the efficacy and acute toxicities of (chemo)radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2017;8(45):78633–41.
    OpenUrl
  69. 69.↵
    Ma WL, Liu R, Huang LH, Zou C, Huang J, Wang J, et al. Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma. Clin Exp Pharmacol Physiol. 2017;44(5):539–48.
    OpenUrl
  70. 70.
    Le Z, Niu X, Chen Y, Ou X, Zhao G, Liu Q, et al. Predictive single nucleotide polymorphism markers for acute oral mucositis in patients with nasopharyngeal carcinoma treated with radiotherapy. Oncotarget. 2017;8(38):63026–37.
    OpenUrl
  71. 71.↵
    Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L, et al. Genetic polymorphisms of Wnt/beta-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma. Oncotarget. 2016;7(50):82528–37.
    OpenUrl
  72. 72.
    Venkatesh GH, Manjunath VB, Mumbrekar KD, Negi H, Fernandes DJ, Sharan K, et al. Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One. 2014;9(3):e89079.
    OpenUrlCrossRefPubMed
  73. 73.
    Ren JH, Dai XF, Yan GL, Jin M, Liu CW, Yang KY, et al. Acute oral mucositis in nasopharyngeal carcinoma patients treated with radiotherapy: association with genetic polymorphism in DNA DSB repair genes. Int J Radiat Biol. 2014;90(3):256–61.
    OpenUrl
  74. 74.↵
    Li H, You Y, Lin C, Zheng M, Hong C, Chen J, et al. XRCC1 codon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients. Radiat Oncol. 2013;8:31.
    OpenUrl
  75. 75.↵
    Pratesi N, Mangoni M, Mancini I, Paiar F, Simi L, Livi L, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol. 2011;99(3):356–61.
    OpenUrlCrossRefPubMed
  76. 76.
    Raturi V, Hojo H, Bhatt MLB, Suhel M, Wu CT, Bei Y, et al. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head and Neck. 2020;42(5):1045–56.
    OpenUrl
  77. 77.
    Lee E, Eum SY, Slifer SH, Martin ER, Takita C, Wright JL, et al. Association Between Polymorphisms in DNA Damage Repair Genes and Radiation Therapy-Induced Early Adverse Skin Reactions in a Breast Cancer Population: A Polygenic Risk Score Approach. Int J Radiat Oncol Biol Phys. 2020;106(5):948–57.
    OpenUrl
  78. 78.↵
    Rattay T, Veal CD, Azria D, Chang-Claude J, Davidson S, Dunning A, et al. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients - results from the REQUITE cohort study. Eur J Cancer. 2020;138(Supplement 1):S12.
    OpenUrl
  79. 79.
    Yang J, Huang Y, Feng Y, Li H, Feng T, Chen J, et al. Associations of genetic variations in mismatch repair genes MSH3 and PMS1 with acute adverse events and survival in patients with rectal cancer receiving postoperative chemoradiotherapy. Cancer Research and Treatment. 2019;51(3):1198–206.
    OpenUrl
  80. 80.↵
    Oliva D, Nilsson M, Strandeus M, Andersson BA, Sharp L, Laytragoon-Lewin N, et al. Individual Genetic Variation Might Predict Acute Skin Reactions in Women Undergoing Adjuvant Breast Cancer Radiotherapy. Anticancer Res. 2018;38(12):6763–70.
    OpenUrlAbstract/FREE Full Text
  81. 81.↵
    Mumbrekar KD, Bola Sadashiva SR, Kabekkodu SP, Fernandes DJ, Vadhiraja BM, Suga T, et al. Genetic Variants in CD44 and MAT1A Confer Susceptibility to Acute Skin Reaction in Breast Cancer Patients Undergoing Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):118–27.
    OpenUrlCrossRefPubMed
  82. 82.
    Chen H, Wu M, Li G, Hua L, Chen S, Huang H. Association between XRCC1 single-nucleotide polymorphism and acute radiation reaction in patients with nasopharyngeal carcinoma: A cohort study. Medicine (Baltimore). 2017;96(44):e8202.
    OpenUrl
  83. 83.
    Guo Z, Wang Y, Zhao Y, Jin Y, An L, Wu B, et al. Genetic polymorphisms of long non-coding RNA GAS5 predict platinum-based concurrent chemoradiotherapy response in nasopharyngeal carcinoma patients. Oncotarget. 2017;8(37):62286–97.
    OpenUrl
  84. 84.
    Osti MF, Nicosia L, Agolli L, Gentile G, Falco T, Bracci S, et al. Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. Am J Clin Oncol. 2017;40(6):535–42.
    OpenUrl
  85. 85.
    Baijer J, Dechamps N, Perdry H, Morales P, Kerns S, Vasilescu A, et al. TNFSF10/TRAIL regulates human T4 effector memory lymphocyte radiosensitivity and predicts radiation-induced acute and subacute dermatitis. Oncotarget. 2016;7(16):21416–27.
    OpenUrl
  86. 86.
    Cordoba EE, Abba MC, Lacunza E, Fernande E, Guerci AM. Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy. Cancer Res. 2016;48(3):948–54.
    OpenUrl
  87. 87.
    Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y, et al. TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated with Chemoradiotherapy. Medicine (United States). 2015;94(45):e1955.
    OpenUrl
  88. 88.
    De Langhe S, Mulliez T, Veldeman L, Remouchamps V, van Greveling A, Gilsoul M, et al. Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. BMC Cancer. 2014;14:711.
    OpenUrlCrossRefPubMed
  89. 89.
    Borghini A, Vecoli C, Mercuri A, Petruzzelli MF, D’Errico MP, Portaluri M, et al. Genetic risk score and acute skin toxicity after breast radiation therapy. Cancer Biotherapy and Radiopharmaceuticals. 2014;29(7):267–72.
    OpenUrl
  90. 90.
    Raabe A, Derda K, Reuther S, Szymczak S, Borgmann K, Hoeller U, et al. Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy. Radiat Oncol. 2012;7:65.
    OpenUrlCrossRefPubMed
  91. 91.↵
    Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, et al. IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res. 2008;14(20):6683–9.
    OpenUrlAbstract/FREE Full Text
  92. 92.↵
    Reyes-Gibby CC, Wang J, Yeung SJ, Chaftari P, Yu RK, Hanna EY, et al. Genome-wide association study identifies genes associated with neuropathy in patients with head and neck cancer. Sci Rep. 2018;8(1):8789.
    OpenUrl
  93. 93.↵
    Lee E, Takita C, Wright JL, Slifer SH, Martin ER, Urbanic JJ, et al. Genome-wide enriched pathway analysis of acute post-radiotherapy pain in breast cancer patients: a prospective cohort study. Hum Genomics. 2019;13.
  94. 94.↵
    King LS, Kozono D, Agre P. From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol. 2004;5(9):687–98.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    Furfari A, Wan BA, Ding K, Wong A, Zhu L, Bezjak A, et al. Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases. Ann Palliat Med. 2017;6(Suppl 2):S248–S56.
    OpenUrl
  96. 96.↵
    Liu J, Tang X, Shi F, Li C, Zhang K, Liu J, et al. Genetic polymorphism contributes to (131)I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. Pharmacogenomics. 2018;19(17):1335–44.
    OpenUrl
  97. 97.
    Lee E, Takita C, Wright JL, Slifer SH, Martin ER, Urbanic JJ, et al. Genome-wide enriched pathway analysis of acute post-radiotherapy pain in breast cancer patients: a prospective cohort study. Hum Genomics. 2019;13(1):28.
    OpenUrl
  98. 98.↵
    Raturi V, Hojo H, Bhatt MLB, Suhel M, Wu CT, Bei Y, et al. Prospective evaluation of XRCC-1 Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head Neck. 2020;42(5):1045–56.
    OpenUrl
  99. 99.↵
    Zhang H, Wang M, Shi T, Shen L, Liang L, Deng Y, et al. TNF rs1799964 as a Predictive Factor of Acute Toxicities in Chinese Rectal Cancer Patients Treated With Chemoradiotherapy. Medicine (Baltimore). 2015;94(45):e1955.
    OpenUrl
  100. 100.↵
    Schack LMH, Naderi E, Fachal L, Dorling L, Luccarini C, Dunning AM, et al. A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis. Br J Cancer. 2022.
  101. 101.↵
    Rattay T, Veal CD, Azria D, Chang-Claude J, Davidson S, Dunning A, et al. Genome wide association study of acute radiation toxicity and quality of life in breast cancer patients - results from the REQUITE cohort study. Eur J Cancer. 2020;138:S12–S.
    OpenUrl
  102. 102.↵
    Neta R, Oppenheim JJ. Radioprotection with cytokines: a clarification of terminology. Cancer Cells. 1991;3(11):457.
    OpenUrlPubMed
  103. 103.
    Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I--mechanisms. J Dent Res. 2007;86(6):491–505.
    OpenUrlCrossRefPubMed
  104. 104.↵
    Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II--clinical perspectives and management. J Dent Res. 2007;86(6):506–18.
    OpenUrlCrossRefPubMed
  105. 105.↵
    Reyes-Gibby CC, El Osta B, Spitz MR, Parsons H, Kurzrock R, Wu X, et al. The influence of tumor necrosis factor-alpha −308 G/A and IL-6 −174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3262–7.
    OpenUrlAbstract/FREE Full Text
  106. 106.↵
    Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain Behav Immun. 2003;17 Suppl 1:S125–31.
    OpenUrlCrossRefPubMedWeb of Science
  107. 107.↵
    Cordoba EE, Abba MC, Lacunza E, Fernande E, Guerci AM. Polymorphic Variants in Oxidative Stress Genes and Acute Toxicity in Breast Cancer Patients Receiving Radiotherapy. Cancer Res Treat. 2016;48(3):948–54.
    OpenUrl
Back to top
Posted November 15, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Systematic Review of Genetic Polymorphisms Associated with Acute Pain and Relevant Acute Toxicities Induced by Radiotherapy for Head and Neck Cancer
Vivian Salama, Yimin Geng, Jillian Rigert, Clifton D. Fuller, Amy C. Moreno, Sanjay Shete, Cielito C. Reyes-Gibby
medRxiv 2022.11.15.22282359; doi: https://doi.org/10.1101/2022.11.15.22282359
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area